Cargando…

The COVID-19 Pandemic and Ophthalmic Care: A Qualitative Study of Patients with Neovascular Age-Related Macular Degeneration (nAMD)

Concerns have been expressed about the relationship between reduced levels of health care utilisation and the COVID-19 pandemic. This study aimed to elicit and explore the views of patients with neovascular age-related macular degeneration (nAMD) regarding the COVID-19 pandemic and their ophthalmic...

Descripción completa

Detalles Bibliográficos
Autores principales:	O’Connor, Seán R., Treanor, Charlene, Ward, Elizabeth, Wickens, Robin A., O’Connell, Abby, Culliford, Lucy A., Rogers, Chris A., Gidman, Eleanor A., Peto, Tunde, Knox, Paul C., Burton, Benjamin J. L., Lotery, Andrew J., Sivaprasad, Sobha, Reeves, Barnaby C., Hogg, Ruth E., Donnelly, Michael
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9368447/ https://www.ncbi.nlm.nih.gov/pubmed/35954844 http://dx.doi.org/10.3390/ijerph19159488

Ejemplares similares

Monitoring for neovascular age-related macular degeneration (AMD) reactivation at home: the MONARCH study
por: Ward, Elizabeth, et al.
Publicado: (2020)

Patient Acceptability of Home Monitoring for Neovascular Age-Related Macular Degeneration Reactivation: A Qualitative Study
por: O’Connor, Seán R., et al.
Publicado: (2022)

New and Innovative Treatments for Neovascular Age-Related Macular Degeneration (nAMD)
por: Patel, Prem, et al.
Publicado: (2021)

Communicating with patients with nAMD and their families during the COVID-19 pandemic
por: Korobelnik, Jean-François, et al.
Publicado: (2020)

Aflibercept Does Not Suppress Angiopoietin-2 in Patients With nAMD or DME
por: Avery, Robert L., et al.
Publicado: (2023)

Ocular Therapeutics and Molecular Delivery Strategies for Neovascular Age-Related Macular Degeneration (nAMD)
por: Sarkar, Aira, et al.
Publicado: (2021)

Neovascular Age-Related Macular Degeneration (nAMD): A Review of Emerging Treatment Options
por: Tan, Colin S, et al.
Publicado: (2022)

A model to quantify the influence of treatment patterns and optimize outcomes in nAMD
por: Ziemssen, Focke, et al.
Publicado: (2022)

Strongest Correlation Between Contrast Sensitivity and Morphological Characteristics in Bilateral nAMD
por: Hoffmann, Laura, et al.
Publicado: (2021)

Impact of intravitreal injection therapy on contrast sensitivity in patients with nAMD and DME
por: Dieke, Sebastian, et al.
Publicado: (2023)

A serum metabolomics study of patients with nAMD in response to anti-VEGF therapy
por: Gao, Yan, et al.
Publicado: (2020)

Treat and Extend Treatment Interval Patterns with Anti-VEGF Therapy in nAMD Patients
por: Skelly, Adrian, et al.
Publicado: (2019)

The Efficacy and Safety of Brolucizumab for the Treatment of nAMD: A Systematic Review and Meta-Analysis
por: Chuan, Junlan, et al.
Publicado: (2022)

Impact on Visual Acuity in Neovascular Age Related Macular Degeneration (nAMD) in Europe Due to COVID-19 Pandemic Lockdown
por: Arruabarrena, Carolina, et al.
Publicado: (2021)

Cost-effectiveness analysis of brolucizumab versus aflibercept for the treatment of neovascular age-related macular degeneration (nAMD) in Italy
por: Ferrante, Nicola, et al.
Publicado: (2022)

nAMD: optimization of patient care and patient-oriented information with the help of an internet-based survey
por: Schmid, Anke, et al.
Publicado: (2022)

Aflibercept treatment for neovascular AMD beyond the first year: consensus recommendations by a UK expert roundtable panel, 2017 update
por: Patel, Praveen J, et al.
Publicado: (2017)

Action on neovascular age-related macular degeneration (nAMD): recommendations for management and service provision in the UK hospital eye service
por: Gale, Richard P., et al.
Publicado: (2019)

A Retrospective Study of Ranibizumab Treatment Regimens for Neovascular Age-Related Macular Degeneration (nAMD) in Australia and the United Kingdom
por: Johnston, Robert L., et al.
Publicado: (2017)

The Clinical Effectiveness of Ranibizumab Treat and Extend Regimen in nAMD: Systematic Review and Network Meta-Analysis
por: Danyliv, Andriy, et al.
Publicado: (2017)

ORCA study: real-world versus reading centre assessment of disease activity of neovascular age-related macular degeneration (nAMD)
por: Liakopoulos, Sandra, et al.
Publicado: (2020)

Erratum to: The Clinical Effectiveness of Ranibizumab Treat and Extend Regimen in nAMD: Systematic Review and Network Meta-Analysis
por: Danyliv, Andriy, et al.
Publicado: (2017)

Systemic counterregulatory response of angiopoietin‐2 after aflibercept therapy for nAMD: a potential escape mechanism
por: Angermann, Reinhard, et al.
Publicado: (2020)

Impact of macular fluid volume fluctuations on visual acuity during anti-VEGF therapy in eyes with nAMD
por: Chakravarthy, Usha, et al.
Publicado: (2021)

Through the Eyes of Patients: Understanding Treatment Burden of Intravitreal Anti-VEGF Injections for nAMD Patients in Norway
por: Reitan, Gudrun, et al.
Publicado: (2023)

Potential for Treatment Interval Extension in Eyes with nAMD Disease Activity Post Loading Phase in HAWK and HARRIER
por: Tadayoni, Ramin, et al.
Publicado: (2023)

Interleukin-1β Level Is Increased in Vitreous of Patients with Neovascular Age-Related Macular Degeneration (nAMD) and Polypoidal Choroidal Vasculopathy (PCV)
por: Zhao, Min, et al.
Publicado: (2015)

Two-Year Outcome of Aflibercept in Patients with Pigment Epithelial Detachment due to Neovascular Age-Related Macular Degeneration (nAMD) Refractory to Ranibizumab
por: Tran, Thi Ha Chau, et al.
Publicado: (2017)

Findings of uncertain significance by optical coherence tomography (OCT) as prognostic factors in neovascular age-related macular degeneration (nAMD) treated with ranibizumab
por: Hayashi-Mercado, Ricardo, et al.
Publicado: (2022)

Analysis of Aflibercept Expression in NHPs following Intravitreal Administration of ADVM-022, a Potential Gene Therapy for nAMD
por: Kiss, Szilárd, et al.
Publicado: (2020)

Predictors of persistent disease activity following anti-VEGF loading dose for nAMD patients in Singapore: the DIALS study
por: Tan, Colin S., et al.
Publicado: (2020)

Corrigendum to “Two-Year Outcome of Aflibercept in Patients with Pigment Epithelial Detachment due to Neovascular Age-Related Macular Degeneration (nAMD) Refractory to Ranibizumab”
por: Tran, Thi Ha Chau, et al.
Publicado: (2018)

An exploratory study evaluating the effects of macular carotenoid supplementation in various retinal diseases
por: Crosby-Nwaobi, Roxanne, et al.
Publicado: (2016)

Contrast sensitivity and binocular reading speed best correlating with near distance vision‐related quality of life in bilateral nAMD
por: Rossouw, Petra, et al.
Publicado: (2020)

Fluctuations in central foveal thickness and association with vision outcomes with anti-VEGF therapy for nAMD: HARBOR post hoc analysis
por: Sheth, Veeral, et al.
Publicado: (2022)

Baseline characteristics and treatment response predictive of nAMD outcomes with ranibizumab therapy in treatment-naive patients: the RACER subgroup analysis
por: Tsai, Ching-Yao, et al.
Publicado: (2023)

Automated deep learning-based AMD detection and staging in real-world OCT datasets (PINNACLE study report 5)
por: Leingang, Oliver, et al.
Publicado: (2023)

Effects of Smoking on Outcomes of Antivascular Endothelial Growth Factor Therapy in Patients with Neovascular Age-Related Macular Degeneration Smoking and Anti-VEGF Therapy in nAMD
por: Kamao, Hiroyuki, et al.
Publicado: (2018)

Aflibercept in wet AMD beyond the first year of treatment: recommendations by an expert roundtable panel
por: McKibbin, M, et al.
Publicado: (2015)

Systematic review of efficacy and meta-analysis of safety of ranibizumab biosimilars relative to reference ranibizumab anti-VEGF therapy for nAMD treatment
por: Hatamnejad, Amin, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_j5v2ge4lg69tstmsq2faagj9v4